Data Curation and Entry in DIDB – Feb Summary

In February, we added 116 citations in DIDB, including 59 in vitro (with 21 articles published in February 2025) and 57 in vivo articles (with 44 articles published in February 2025).

4 NDA/BLAs approved in 2024, including concizumab (ALHEMO), ensifentrine (OHTUVAYRE), marstacimab (HYMPAVZI), vanzacaftor and tezacaftor and deutivacaftor (ALYFTREK), and 1 NDA approved in 2025, namely treosulfan (GRAFAPEX), were also curated in DIDB.

You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.

As always, feel free to contact us if you have any questions or comments.